BenzingaT3·9mo ago
PTH Invesco Exchange-Traded Fund Trust Invesco Dorsey Wright Healthcare Momentum ETF
ETF 58.91 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PTH
$58.91
—
Key stats
$58.91
After hours
$58.91
+0.00%
- 52-Week Range
- $45.83 – $64.10
- YTD
- +19.64%
- IV Rank (30D)
- 70.23
- Straddle Price
- $4.05
- Open
- $59.12
- Day Range
- $58.27 – $59.80
- Volume
- 22,874
- Prev Close
- $59.62
About
Invesco Exchange-Traded Fund Trust Invesco Dorsey Wright Healthcare Momentum ETF (PTH) ETF
No description available.
- Exchange
- XNAS
- Inception
- 2006-10-12
- Has Options
- Yes
Fund profile
holdings as of Oct 16, 2026third-party datathrough Jul 2026flows, SEC filings
- Expense ratio
- 0.60% prospectus, filed Aug 27, 2025
- Assets
- $292M shares × price, Oct 21, 2026
- Trailing yield
- 2.56% paid quarterly
- Average daily volume
- $2.3M 30 sessions
- Holdings
- 55 top 10 are 36.4%
- Listed
- Oct 12, 2006 Nasdaq
- Tracking difference
- -0.79 pts vs index, after fees, FY 2026
Cost23
Liquidity46
Scale54
Diversification70
Moves with. Small caps over large (17% of its variance, beta 0.95); Value over growth (10% of its variance, beta -0.54); US large-cap stocks (8% of its variance, beta 0.36); Long Treasuries (4% of its variance, beta 0.42). These factors explain 41% of its daily moves over the last year.
Stated objective. The Invesco Dorsey Wright Healthcare Momentum ETF (the Fund) seeks to track the investment results (before fees and expenses) of the Dorsey Wright Healthcare Technical Leaders TM Index (the Underlying Index). (from the fund's prospectus)
All 55 holdingsFlow historySimilar fundsOverlap toolAll Health Care ETFs
Fund flows
through Jul 2026SEC filings- Jul 2026
- +$106M latest reported month
- Latest 3 months
- +$100M +42.3% of assets
- Latest 12 months
- +$99M +42.2% of assets
View as a table
| Month | Net flow |
|---|---|
| Jul 2026 | +$106M |
| Jun 2026 | −$2.0M |
| May 2026 | −$4.1M |
| Apr 2026 | −$1.0M |
| Mar 2026 | −$3.3M |
| Feb 2026 | −$1.5M |
| Jan 2026 | −$14M |
| Dec 2025 | +$21M |
| Nov 2025 | +$3.2M |
| Oct 2025 | −$973K |
| Sep 2025 | −$2.1M |
| Aug 2025 | −$1.2M |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 84 months ago
Similar funds
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| FMEDFidelity Disruptive Medicine ETF | 27% | 0.50% | $52M | +20.6% | compare |
| GNMXCorgi Genomics & Precision Medicine ETF | 25% | 0.35% | $1.3M | — | compare |
| HELXFranklin Genomic Advancements ETF | 24% | 0.50% | $35M | +26.9% | compare |
| XBIState Street SPDR S&P Biotech ETF | 23% | 0.35% | $10.4B | +38.7% | compare |
| EKGFirst Trust Nasdaq Lux Digital Health Solutions ETF | 23% | 0.65% | $9.5M | +32.3% | compare |
Ranked by how much of the two portfolios is the same securities.
Look-through: what the holdings say
weights as of Oct 16, 2026third-party data- Holdings vs fair value
- +3.1% 34% under, 34% over · 100% covered
- Price / earnings
- — 60% loss-making · 98% covered
- Price / book · sales
- 7.4 · 4.3 revenue growth +13.8%
- Above 200-day average
- 87% 56% above 50-day · by weight
- Short interest
- 11.7% of float, weighted · 5.5 days to cover
- Insider buying
- 3% of weight had net insider buying, 90 days; 78% net selling
- 13F holders
- +5.0% change in shares held by institutions, latest quarter
- Reporting earnings
- 22.0% of weight in 7 days; 75.9% in 14
Holdings reporting in the next 14 days · weighted implied move this week 3.29%
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
What changed in the portfolio
Apr 30, 2026 → Jul 31, 2026| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Exit | PRAXPraxis Precision Medicines, Inc. | 5.08% | — | — |
| New position | GHGuardant Health, Inc. | — | 4.97% | — |
| New position | RVMDRevolution Medicines, Inc. | — | 4.94% | — |
| Exit | UTHRUnited Therapeutics Corp. | 3.43% | — | — |
| Exit | THCTenet Healthcare Corp. | 3.04% | — | — |
| Exit | TERNTerns Pharmaceuticals, Inc. | 2.86% | — | — |
| Exit | HCAHCA Healthcare, Inc. | 2.78% | — | — |
| Exit | NKTRNektar Therapeutics | 2.57% | — | — |
| Exit | CELCCelcuity Inc. | 2.53% | — | — |
| Exit | IONSIonis Pharmaceuticals, Inc. | 2.37% | — | — |
Under the hood
fiscal year to Apr 30, 2026SEC census- Authorized participants
- 6 active of 40 with agreements; top 3 did 87%
- Created · redeemed
- $29M · $40M over the fiscal year
- Redemptions in kind
- 99% creations 100% in kind
- Creation unit
- 10,000 shares
- Securities lending
- 25.61% of assets on loan on average; earned 13.2 bp
- Return vs index
- -0.79 pts after fees; -0.04 before; daily s.d. 0.18
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
ETF Profile
holdings as of 2026-07-31
Holdings
57
AUM
$300.5M
Provider
Nport
Inception
2006-10-12
Exchange
XNAS
Data As Of
2026-07-31
Expense Ratio
0.60%
Dividend Yield
2.56%
Distribution
Quarterly
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2025-12-22 | 2025-12-26 | $1.5265 | CD |
| 2024-06-24 | 2024-06-28 | $0.0255 | CD |
Asset Allocation
Top Holdings
top 50 of 57 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | Invesco Private Prime Fund | 20.79% | Short-term investment | US |
| — | Invesco Private Government Fund | 6.83% | Short-term investment | US |
| GH | Guardant Health, Inc. | 4.97% | Equity (common) | US |
| ROIV | Roivant Sciences Ltd. | 4.95% | Equity (common) | BM |
| RVMD | Revolution Medicines, Inc. | 4.94% | Equity (common) | US |
| AXSM | Axsome Therapeutics, Inc. | 4.12% | Equity (common) | US |
| BTSG | BrightSpring Health Services, Inc. | 4.03% | Equity (common) | US |
| LQDA | Liquidia Corp. | 3.01% | Equity (common) | US |
| ERAS | Erasca, Inc. | 2.94% | Equity (common) | US |
| ORKA | Oruka Therapeutics, Inc. | 2.74% | Equity (common) | US |
| TXG | 10x Genomics, Inc. | 2.27% | Equity (common) | US |
| RLAY | Relay Therapeutics, Inc. | 2.25% | Equity (common) | US |
| TNGX | Tango Therapeutics Inc. | 2.16% | Equity (common) | US |
| TVTX | Travere Therapeutics, Inc. | 2.16% | Equity (common) | US |
| OSCR | Oscar Health, Inc. | 2.10% | Equity (common) | US |
| ILMN | Illumina, Inc. | 2.08% | Equity (common) | US |
| AGL | agilon health, Inc. | 2.07% | Equity (common) | US |
| AXGN | Axogen, Inc. | 2.06% | Equity (common) | US |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 2.01% | Equity (common) | US |
| SYRE | Spyre Therapeutics, Inc. | 2.01% | Equity (common) | US |
| REPL | Replimune Group, Inc. | 1.93% | Equity (common) | US |
| JAZZ | Jazz Pharmaceuticals PLC | 1.93% | Equity (common) | IE |
| MRNA | Moderna, Inc. | 1.90% | Equity (common) | US |
| CYTK | Cytokinetics, Inc. | 1.89% | Equity (common) | US |
| VTRS | Viatris Inc. | 1.82% | Equity (common) | US |
| CNC | Centene Corp. | 1.79% | Equity (common) | US |
| HUM | Humana Inc. | 1.77% | Equity (common) | US |
| LGND | Ligand Pharmaceuticals Inc. | 1.74% | Equity (common) | US |
| CORT | Corcept Therapeutics Inc. | 1.71% | Equity (common) | US |
| ELVN | Enliven Therapeutics, Inc. | 1.70% | Equity (common) | US |
| TWST | Twist Bioscience Corp. | 1.59% | Equity (common) | US |
| HIMS | Hims & Hers Health, Inc. | 1.57% | Equity (common) | US |
| MBX | MBX Biosciences, Inc. | 1.53% | Equity (common) | US |
| ARQT | Arcutis Biotherapeutics, Inc. | 1.53% | Equity (common) | US |
| ESTA | Establishment Labs Holdings Inc. | 1.51% | Equity (common) | VG |
| QURE | uniQure N.V. | 1.50% | Equity (common) | NL |
| PACS | PACS Group, Inc. | 1.33% | Equity (common) | US |
| EXEL | Exelixis, Inc. | 1.31% | Equity (common) | US |
| TRVI | Trevi Therapeutics, Inc. | 1.17% | Equity (common) | US |
| KRYS | Krystal Biotech, Inc. | 1.17% | Equity (common) | US |
| NHC | National HealthCare Corp. | 1.12% | Equity (common) | US |
| AMRX | Amneal Pharmaceuticals, Inc. | 1.12% | Equity (common) | US |
| ALKS | Alkermes PLC | 1.10% | Equity (common) | IE |
| VCYT | Veracyte, Inc. | 1.09% | Equity (common) | US |
| NEO | NeoGenomics, Inc. | 1.08% | Equity (common) | US |
| NUVB | Nuvation Bio Inc. | 1.06% | Equity (common) | US |
| TGTX | TG Therapeutics, Inc. | 1.06% | Equity (common) | US |
| ABSI | AbSci Corp. | 0.99% | Equity (common) | US |
| DNLI | Denali Therapeutics Inc. | 0.97% | Equity (common) | US |
| IRON | Disc Medicine, Inc. | 0.89% | Equity (common) | US |
Geographic Breakdown
Non-Equity Breakdown
Invesco Dorsey Wright Healthcare Momentum ETF ·
NPORT-P period 2026-07-31
(filed 2026-09-28)
Net assets:
$235M
· 57 total positions
· equity 100.04%
· non-equity 27.70%
Non-equity holdings
— 3 positions,
27.70% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 27.70% | $65.2M | 3 |
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 4.15% | -14.83% | 1.57% | 1.53% | 6.13% | -1.88% | -0.55% |
| Feb | -5.53% | -0.85% | -6.96% | 11.59% | -3.54% | 0.96% | -0.72% |
| Mar | -7.50% | 3.76% | -3.97% | -5.46% | -1.52% | -1.07% | -2.63% |
| Apr | -1.80% | -10.77% | 6.26% | -6.74% | 5.22% | 2.62% | -0.87% |
| May | -0.20% | -2.15% | -3.77% | 1.57% | -7.80% | 3.03% | -1.55% |
| Jun | 6.90% | -2.29% | 2.96% | 1.66% | 4.68% | 17.53% | 5.24% |
| Jul | -1.42% | 7.45% | -2.45% | 4.34% | -0.28% | -3.62% | 0.67% |
| Aug | 2.49% | 5.02% | -4.00% | 6.08% | 6.08% | 4.58% | 3.38% |
| Sep | -6.60% | -7.01% | -10.30% | 1.97% | 10.39% | -0.28% | -1.97% |
| Oct | 1.48% | 3.12% | -7.49% | -2.93% | 9.82% | -1.26%* | 0.46% |
| Nov | -9.33% | -0.50% | 9.02% | -0.66% | 13.01% | -- | 2.31% |
| Dec | 5.81% | -0.97% | 14.51% | -10.67% | -6.65% | -- | 0.41% |
| Total | -12.40% | -20.30% | -7.31% | 0.28% | 38.51% | 20.86% | 3.27% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $59.00
SMA 50: $60.56
SMA 200: $54.27
Current: $58.53
EMA 12: $58.41
EMA 26: $59.12
MACD: -0.7130 | Signal: 0.0945
BEARISH
ADX (14): 13.87
RANGE
+DI: 25.26
−DI: 28.82
Momentum Oscillators
RSI (14): 47.51
NEUTRAL
Stoch %K: 52.63
Stoch %D: 39.83
Williams %R: -54.99
Volume & Volatility
BB Upper: $62.43
BB Lower: $55.58
NEUTRAL
OBV: 51,485
Vol SMA 20: 36,309
Vol ROC: -56.05%
ATR: $1.48
True Range: $1.53
HV 20: 32.1%
HV 30: 29.8%
HV 60: 29.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
- Overall assessment: NEUTRAL with confidence level 6/10
- Key drivers and primary risks:
- Bullish trend indicators (MACD, SMA 12) and recent FDA approval news
- Bearish momentum signals (RSI, Stochastic %K) and historical volatility
- Investment thesis: PTH has a strong technical setup with short-term bullish momentum, but faces medium-term resistance at the upper Bollinger Band. Recent positive news from the FDA could catalyze a breakout.
- Recent news sentiment impact: Neutral to positive, with no significant bearish headlines.
Technical Analysis
Trend Direction
- Short-term (1-4 weeks): Uptrend
- Medium-term (1-3 months): Range-bound
- Long-term (3-12 months): Bullish
Support/Resistance Levels
- Key price levels: $48.11 (SMA 200), $50.83 (SMA 50), $53.25 (Upper Bollinger Band)
Momentum Signals
- RSI interpretation: Neutral, as the indicator has fallen from overbought to oversold territory.
- MACD signal: Bullish, with a bullish crossover above the signal line.
- Bollinger Bands position: Oversold, indicating potential for mean reversion or breakout.
Volume Analysis
- Volume trends: Weakness in recent trading volume suggests decreased institutional interest.
- Institutional interest signals: Low volume and no significant buying pressure.
News & Sentiment Analysis
Recent Headlines Summary
- Positive news from FDA approval and neutral market commentary dominate the recent headlines.
Sentiment Assessment
- Aggregate sentiment: Neutral, with a slight lean towards positive due to the FDA approval.
Catalyst Identification
- Upcoming catalysts:
- Earnings report (no specific date available)
- Product launches or regulatory changes in the healthcare sector
Market Narrative
- News aligns with short-term bullish technical signals and medium-term range-bound expectations. However, there is a risk of mean reversion or a breakdown if the stock fails to break above the upper Bollinger Band.
Risk & Volatility Assessment
Beta Interpretation
- Risk relative to market: High, with a beta of 1.04 (above average).
Volatility Regime
- Current vs historical volatility levels: Above average, indicating increased risk.
Options Market Signals
- IV rank: 100.0% (High) - shows historically high volatility.
- Put/call ratios: Bullish sentiment dominates, with more calls traded than puts.
Downside Protection
- Support levels:
- SMA 200 ($48.11)
- Lower Bollinger Band ($49.57)
Market Context & Positioning
Sector Performance
- Relative strength vs sector/market: Above average in the healthcare sector and market.
Institutional Activity
- Volume patterns suggesting institutional interest: Weakness in recent trading volume suggests decreased institutional interest.
Correlation Analysis
- How stock moves relative to market (R-squared interpretation): 0.53, indicating a strong positive correlation with the broader market.
Relative Valuation
- Position within trading range: Within the middle of its recent trading range, suggesting fair value.
Key Levels & Action Items
Critical Price Levels
- Support/resistance levels:
- SMA 200 ($48.11)
- Upper Bollinger Band ($53.25)
Breakout/Breakdown Levels
- Technical levels that could trigger significant moves:
- Break above the upper Bollinger Band for a potential breakout
- Failure to break above the SMA 50 or lower Bollinger Band for a potential breakdown
Time-Sensitive Catalysts
- Earnings report (no specific date available)
- Product launches or regulatory changes in the healthcare sector
Risk Management
- Stop-loss levels:
- Below SMA 200 ($48.11) for a stop-loss below this level
- Above SMA 50 ($50.83) for a stop-loss above this level
- Position sizing considerations: Consider reducing position size due to high volatility and beta.
Generated
News
All PTH news →
Zacks Investment ResearchT3·32mo ago
Zacks Investment ResearchT3·44mo ago
Zacks Investment ResearchT3·47mo ago
Zacks Investment ResearchT3·48mo ago
Zacks Investment ResearchT3·49mo ago
Zacks Investment ResearchT3·50mo ago
Zacks Investment ResearchT3·50mo ago
Zacks Investment ResearchT3·52mo ago
Zacks Investment ResearchT3·52mo ago
Showing 1–10 of 20
Page 1 of 2
PTH Options Activity & IV Rank
PTH IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 30.5%
7-DTE IV: —
Expected Move: $4.05
7-DTE Move: $4.05
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 0
Put Volume: 1
P/C Volume: —
Call OI: 0
Put OI: 1
P/C OI: —
Total OI: 1
ATM Options Pricing
ATM Call: $1.95
ATM Put: $2.10
Call %: 3.3%
Put %: 3.6%
Chain Summary
Chain Volume: 7
Chain OI: 6
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 30.6% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)70.2MediumOct 22
Straddle Price (30 DTE)$4.05Oct 22
Beta Analysis
Risk Metrics
Beta: 0.9999
Alpha: 13.45%
Correlation: 0.4752
R-Squared: 22.6%
Stock Volatility: 26.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
PTH Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
14.99K
SI % of Float
0.31%
Days to Cover
1.00
Short Vol Ratio
78.3%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-21
PTH Constituent Performance
Click any bar to view the full quote for that stock.
PTH Constituents (54 of 54)
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| GH | Guardant Health, Inc. | 4.97% | $162.94 | -2.23% | -1.77% | -7.66% |
| ROIV | Roivant Sciences Ltd. | 4.95% | $37.45 | +1.77% | +10.02% | +3.65% |
| RVMD | Revolution Medicines, Inc. | 4.94% | $187.69 | -3.39% | -0.83% | -6.09% |
| AXSM | Axsome Therapeutics, Inc. | 4.12% | $156.07 | -0.15% | -3.54% | -20.38% |
| BTSG | BrightSpring Health Services, Inc. | 4.03% | $60.86 | -2.41% | -2.41% | +8.64% |
| LQDA | Liquidia Corp. | 3.01% | $39.69 | +2.14% | +14.12% | -44.06% |
| ERAS | Erasca, Inc. | 2.94% | $14.04 | -3.11% | -5.58% | -3.31% |
| ORKA | Oruka Therapeutics, Inc. | 2.74% | $81.15 | +1.54% | +9.86% | -5.08% |
| TXG | 10x Genomics, Inc. | 2.27% | $69.75 | -7.73% | -3.65% | -17.07% |
| RLAY | Relay Therapeutics, Inc. | 2.25% | $18.34 | -0.38% | +6.01% | +3.44% |
| TNGX | Tango Therapeutics Inc. | 2.16% | $27.93 | +3.52% | +23.04% | +13.40% |
| TVTX | Travere Therapeutics, Inc. | 2.16% | $52.43 | -0.29% | -0.68% | -13.51% |
| OSCR | Oscar Health, Inc. | 2.10% | $33.32 | -0.39% | -0.45% | +15.41% |
| ILMN | Illumina, Inc. | 2.08% | $269.4 | -4.76% | +0.55% | -1.64% |
| AGL | agilon health, Inc. | 2.07% | $90.29 | -0.77% | +2.08% | +19.07% |
| AXGN | Axogen, Inc. | 2.06% | $36.68 | +0.55% | +2.95% | -15.33% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 2.01% | $58.36 | -0.82% | -0.24% | -11.67% |
| SYRE | Spyre Therapeutics, Inc. | 2.01% | $92.33 | -0.67% | +15.27% | +6.02% |
| REPL | Replimune Group, Inc. | 1.93% | $11.99 | +2.30% | +2.04% | -4.84% |
| JAZZ | Jazz Pharmaceuticals PLC | 1.93% | $214.65 | +1.26% | +0.11% | -9.15% |
| MRNA | Moderna, Inc. | 1.90% | $202.63 | -17.57% | -14.32% | +4.01% |
| CYTK | Cytokinetics, Inc. | 1.89% | $62.33 | -0.84% | -2.49% | -5.07% |
| VTRS | Viatris Inc. | 1.82% | $18.48 | +0.16% | +1.43% | +6.08% |
| CNC | Centene Corp. | 1.79% | $71.24 | +1.42% | +1.04% | +15.05% |
| HUM | Humana Inc. | 1.77% | $420.97 | -1.05% | -2.60% | +10.69% |
| LGND | Ligand Pharmaceuticals Inc. | 1.74% | $307.82 | -2.21% | +3.12% | +2.94% |
| CORT | Corcept Therapeutics Inc. | 1.71% | $107.5 | -7.55% | -5.18% | -9.29% |
| ELVN | Enliven Therapeutics, Inc. | 1.70% | $41.93 | +0.26% | +6.61% | -7.17% |
| TWST | Twist Bioscience Corp. | 1.59% | $135.47 | -9.16% | -6.24% | -26.39% |
| HIMS | Hims & Hers Health, Inc. | 1.57% | $29.13 | -0.27% | -0.85% | -0.51% |
| MBX | MBX Biosciences, Inc. | 1.53% | $50.46 | -6.43% | -0.49% | -8.90% |
| ARQT | Arcutis Biotherapeutics, Inc. | 1.53% | $32.2 | +1.04% | +10.65% | +22.57% |
| ESTA | Establishment Labs Holdings Inc. | 1.51% | $63.52 | +1.99% | +3.52% | -3.14% |
| QURE | uniQure N.V. | 1.50% | $23.11 | +1.85% | +2.62% | -39.69% |
| PACS | PACS Group, Inc. | 1.33% | $47.5 | +1.58% | -0.52% | +14.57% |
| EXEL | Exelixis, Inc. | 1.31% | $65.31 | +1.13% | +3.95% | +12.70% |
| TRVI | Trevi Therapeutics, Inc. | 1.17% | $12.94 | +1.33% | +6.85% | -11.82% |
| KRYS | Krystal Biotech, Inc. | 1.17% | $320.13 | -0.63% | -2.99% | -7.20% |
| NHC | National HealthCare Corp. | 1.12% | $243.07 | +3.17% | -1.00% | +9.69% |
| AMRX | Amneal Pharmaceuticals, Inc. | 1.12% | $20.48 | +1.39% | +6.39% | +3.41% |
| ALKS | Alkermes PLC | 1.10% | $44.18 | +1.61% | +10.17% | +8.31% |
| VCYT | Veracyte, Inc. | 1.09% | $46.04 | -0.39% | +3.72% | -5.15% |
| NEO | NeoGenomics, Inc. | 1.08% | $16.39 | -3.81% | -4.99% | -16.21% |
| NUVB | Nuvation Bio Inc. | 1.06% | $4.7 | -3.09% | -1.05% | -17.98% |
| TGTX | TG Therapeutics, Inc. | 1.06% | $53.16 | -0.08% | -5.07% | -7.58% |
| ABSI | AbSci Corp. | 0.99% | $9.37 | -6.67% | +5.52% | -9.42% |
| DNLI | Denali Therapeutics Inc. | 0.97% | $18.66 | -0.11% | +1.74% | -8.84% |
| IRON | Disc Medicine, Inc. | 0.89% | $75.03 | -1.28% | +32.44% | +12.93% |
| AMN | AMN Healthcare Services, Inc. | 0.82% | $46.82 | +8.86% | +17.05% | +35.47% |
| GRDN | Guardian Pharmacy Services, Inc. | 0.80% | $39.59 | +1.56% | -0.23% | -5.26% |